4-aminopyridine and Day Blindness

4-aminopyridine has been researched along with Day Blindness in 5 studies

Research

Studies (5)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity

Intent to treat analysis of treatment effect in primary endpoint EDTRS 5% Contrast Sensitivity. Change in the number of letters able to read while on Dalfampridine and Placebo relative to their baseline scores. (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)

Changes in Color Vision Total Error Score From Baseline Based Upon the Farnsworth Munsell Hue 100 Sort Test (FM100).

Dalfampridine will change color vision Total Error Scores from baseline on the Farnsworth Munsell 100 Hue Sort Test. Farnsworth Munsell 100 Hue Test requires placing 100 color palettes in the correct order based upon color hue. Scores are determined by the frequency and severity of any displacement in the correct order. One error equates to one misplaced hue, by one step or position. An error score greater than 500 indicates virtually no color discrimination. An error score of 0 indicates no errors in ordering the hues. A Total Error Score of 0 to 128 could be seen in a normal population. (NCT01337986)
Timeframe: Visit 1 (Week 0 - baseline), Visit 2 (Week 3 - postintervention 1) and Visit 3 (Week 8 - post intervention 2)

Dalfampridine Effect on Quality of Life Change From Baseline.

Dalfampridine treatment will result in change in quality of life. The National Eye Institute Visual Function Questionnaire consists of 25 questions characterizing visual function at home and in the community. Score ranges from 100 (best) to 0 (worst). (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)

Difference in EDTRS 5% Contrast Sensitivity (LogMAR Score) at Visits 2 and 3 Relative to Visit 1

Intent to treat analysis of treatment effect in primary endpoint EDTRS 5% Contrast Sensitivity. Improvement from baseline scores. (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)

Difference in Pelli- Robson Score at Visits 2 and 3 Relative to Visit 1

Difference in Pelli- Robson Score at Visits 2 and 3 Relative to Visit 1 on Dalfampridine vs Placebo. Pelli-Robson is scored based upon the numbers read on the chart converted to LogMAR units. The scale is 0.00 (worst) to 2.35 (best). (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)

Efficacy of Dalfampridine on Visual Function Assessed by Change From Baseline in Raw Letters by EDTRS 5% Contrast Sensitivity

Per Protocol Analysis to assess difference in number of letters on the EDTRS 5% Contrast Sensitivity (LogMAR) Chart scores at visits 2 and 3 Relative to Visit 1 (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)

Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores

Per Protocol Analysis to assess differences in EDTRS 5% Contrast Sensitivity (LogMAR) Scores at visits 2 and 3 Relative to Visit 1 on patients taking Dalfampridine vs Placebo. (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)

Percentage of Eyes That Improved by 2 Lines (10 Letters) on the Sloan 5% Contrast Sensitivity Chart

(NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)

Percentage of Eyes That Improved by One-line (5 Letters)

Percentage of eyes that improved by one-line (5 letters) on the 5% contrast sensitivity chart (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)

Visual Evoked Potential P100 Latency Per Treatment Arm

Visual evoked potential 60min P100 latency on dalfampridine vs. placebo. (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)

Odds Ratio Quartile of Visual Field Index

"The Visual Field Index (VFI) is a global index that assigns a number between 1% to 100% based on an aggregate percentage of visual function, with 100% being a perfect age-adjusted visual field.~Probability of falling in the best quartile for visual field (VFI) measures (Q1), relative to the three next quartiles for worse VFIs (Q2-4), while on Dalfampridine vs Placebo. Due to the clustered observations at different times in a cross-over design, the visual field data is not suited to a normal theory model and should not be expressed as a continuous variable. Thus, a categorical model that uses a multinomial distribution for measurement of 4 categories was selected for proper statistical modeling, with results expressed as odds ratios." (NCT01337986)
Timeframe: Visit 1 (Week 0 - baseline), Visit 2 (Week 3 - post intervention 1) and Visit 3 (Week 8 - post intervention 2)

Trials

2 trials available for 4-aminopyridine and Day Blindness

Other Studies

3 other studies available for 4-aminopyridine and Day Blindness